Generic Medicine Info
Should be taken with food. Take immediately before or up to 30 min before meals.
IDDM, diabetic ketoacidosis.
Special Precautions
Patient w/ adrenal and/or pituitary impairment. Severe renal and moderate to severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor wt, lipid profile; fasting blood glucose and glycosylated Hb (HbA1c) levels.
Adverse Reactions
Hypoglycaemia, upper resp tract infection, back pain, flu-like symptoms, dizziness, arthropathy, diarrhoea, accidental trauma, bronchitis, cough.
Drug Interactions
CYP2C9 and CYP3A4 inhibitors or inducers may alter metabolism of nateglinide. Increased hypoglycaemic effects w/ MAOIs, nonselective β-adrenergic blockers, NSAIDs, salicylates. Decreased hypoglycaemic effects w/ corticosteroids, sympathomimetic agents, thiazide diuretics, thyroid hormones.
CIMS Class
ATC Classification
A10BX03 - nateglinide ; Belongs to the class of other blood glucose lowering drugs, excluding insulins. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on nateglinide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in